ADHD Drug Cardiovascular Risk Should Be Extended to Strattera, Cmte. Says

Warnings about cardiovascular risk associated with pediatric use of attention deficit/hyperactivity disorder treatments should be extended to Lilly's Strattera, FDA's Pediatric Advisory Committee recommended